PRLD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRLD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Prelude Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Prelude Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Prelude Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Prelude Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Prelude Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 0 | / ( | (0 | + | 0) | / | 1 ) |
= | 0 | / | 0 | ||||
= | N/A |
Prelude Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover (Q: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Dec. 2023 ) | / ( | (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) |
= | 0 | / ( | (0 | + | 0) | / | 1 ) |
= | 0 | / | 0 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (NAS:PRLD) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Prelude Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Prelude Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Prelude Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Krishna Vaddi | director, officer: President, CEO | C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803 |
Bryant David Lim | officer: Chief Legal Counsel, Corp Sec. | C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341 |
Laurent Chardonnet | officer: Chief Financial Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
David P Bonita | director, 10 percent owner | C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jane Huang | officer: President, CMO | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
L.p. 667, | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors (gp) Llc | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Felix Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Deborah Morosini | officer: EVP, Chief of Clinical Affairs | C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803 |
Andrew Combs | officer: EVP, Head of Chemistry | C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803 |
David J Mauro | officer: Chief Medical Officer | 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977 |
From GuruFocus
By Marketwired • 10-14-2023
By sperokesalga sperokesalga • 05-17-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 03-09-2022
By GuruFocusNews GuruFocusNews • 05-10-2022
By Value_Insider Value_Insider • 11-14-2022
By GuruFocusNews GuruFocusNews • 03-11-2022
By Marketwired • 08-29-2023
By GuruFocus Research • 05-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.